2 Infant Bacterial Therapeutics AB 142 180 227 23 55 94 89 - - PowerPoint PPT Presentation

▶
2 infant bacterial therapeutics ab 142 180 227 23 55 94
SMART_READER_LITE
LIVE PREVIEW

2 Infant Bacterial Therapeutics AB 142 180 227 23 55 94 89 - - PowerPoint PPT Presentation

Feb 18, 2023 270 likes •700 views

Disclaimer 142 180 227 23 55 94 89 89 89 191 191 191 148 138 84 13 13 13 2 Infant Bacterial Therapeutics AB 142 180 227 23 55 94 89 89 89 191 191 191 148 138 84 13 13 13 3 The IBT concept 142 180 227 23

slide-1
SLIDE 1
slide-2
SLIDE 2

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

Disclaimer

2

slide-3
SLIDE 3

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

3

Infant Bacterial Therapeutics AB

slide-4
SLIDE 4

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

The IBT concept

4

slide-5
SLIDE 5

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

slide-6
SLIDE 6

6

slide-7
SLIDE 7

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

7

CDC/NCHS, National Vital Statistics System

Mortality

slide-8
SLIDE 8

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

8

slide-9
SLIDE 9

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

9

slide-10
SLIDE 10

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

10

slide-11
SLIDE 11

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

501-750g 42.0% 751-1,000g 29.4% 1,001-1250g 21.3% 1,251-1,500g 15.9% 1,501-2,500g 12,7%

11

slide-12
SLIDE 12

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

12

Ganapathy 2011, Niño 2016

NEC Economic Burden is estimated to be 20% of the total cost of initial care and $5 Billion spent annually on NEC in the USA

slide-13
SLIDE 13

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

slide-14
SLIDE 14

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

14

slide-15
SLIDE 15

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

15

slide-16
SLIDE 16

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

slide-17
SLIDE 17

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

17

slide-18
SLIDE 18

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

18 2013 2016 2020 2030 2035

+ 2y pedia

slide-19
SLIDE 19

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

19

slide-20
SLIDE 20

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

Improved survival from NEC Reduced intestinal damage

Control NEC NEC + L. reuteri

NEC Control NEC+Lr NEC NEC NEC+Lr NEC+Lr 20

slide-21
SLIDE 21

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

Walter et al., 2011 Walter et al., 2011

Schaefer 2010, Walter 2011, Wu 2013, West 2020

21

slide-22
SLIDE 22

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

NEC

Source Warner et al, 2016, Pammi et al. 2017

Controls

Days after birth

22

slide-23
SLIDE 23

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

Number of positive feces samples for identified pathogens from 30 infants

* *

P≤0.05

*

23

slide-24
SLIDE 24

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

  • L. reuteri inhibits S. aureus

Bacteria ▪ Bacillus subtilis ▪ Listeria monocytogenes ▪ Campylobacter jejuni ▪ Porphyromonas gingivalis ▪ Clostridium perfringens ▪ Prevotella intermedia ▪ Clostridium difficile ▪ Pseudomonas fluorescens ▪ Escherichia coli (patogena) ▪ Salmonella typhimurium ▪ Enterobacter sakazakii ▪ Shigella spp ▪ Fusobacterium nucleatum ▪ Staphylococcus aureus ▪ Helicobacter pylori ▪ Streptococcus mutans Yeast and fungi ▪ Candida albicans ▪ Aspergillus flavus ▪ Fusarium samiaciens

24

slide-25
SLIDE 25

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

*

  • L. reuteri

Placebo

FoxP3

Treg

P≤0.05

*

25

slide-26
SLIDE 26

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

Treg cell modulation Teff cell modulation

A B

  • L. reuteri

L. acidophilus

  • L. reuteri

L. acidophilus

FoxP3

Treg

Teff

26

slide-27
SLIDE 27

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

  • No. of episodes of

evacuations

  • No. of episodes of

regurgitation

Formula + L. reuteri

*

P≤0.05

*

Formula + L. reuteri Formula + placebo

* * *

Formula + placebo 27

slide-28
SLIDE 28

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

28

slide-29
SLIDE 29

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

slide-30
SLIDE 30

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

30

* reduction in episodes of feeding intolerance ** reduction in time to full enteral feeding

slide-31
SLIDE 31

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

31

slide-32
SLIDE 32

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

Favors L. reuteri Favors placebo

32

slide-33
SLIDE 33

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94 Kornhauser 2010

33

slide-34
SLIDE 34

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

slide-35
SLIDE 35

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

35

slide-36
SLIDE 36

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

http://ibtherapeutics.com/wp-content/uploads/2016/03/Hot-topics-poster-1128.pdf 36

slide-37
SLIDE 37

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

37

slide-38
SLIDE 38

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

❏ ❏ ❏ ❏ ❏

38

slide-39
SLIDE 39

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

39

✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔

slide-40
SLIDE 40

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94

slide-41
SLIDE 41

89 89 89 148 138 84 191 191 191 13 13 13 142 180 227 23 55 94